Cannabis Bioscience International Holdings, Inc. (CBIH) EBITDA Margin (2022 - 2026)

Cannabis Bioscience International Holdings has disclosed EBITDA Margin across 5 years of filings, most recently posting 832.3% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 3324.0% year-over-year to 832.3%; the TTM figure through Feb 2026 stood at 322.6% (down 23069.0% YoY), while the FY2025 annual figure was 139.05%, up 5631.0% from the prior year.
• EBITDA Margin came in at 832.3% for Q1 2026 at Cannabis Bioscience International Holdings, down from 180.0% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 39.06% in Q2 2024 to a low of 865.54% in Q1 2025.
• Average EBITDA Margin over 5 years is 353.4%, with a median of 275.89% recorded in 2023.
• Year-over-year, EBITDA Margin surged 55324 bps in 2024 and tumbled 42619 bps in 2025.
• Over 5 years, EBITDA Margin stood at 222.34% in 2022, then surged by 33 bps to 148.26% in 2023, then jumped by 46 bps to 80.31% in 2024, then sank by 124 bps to 180.0% in 2025, then tumbled by 362 bps to 832.3% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 832.3% in Q1 2026, 180.0% in Q4 2025, and 309.02% in Q3 2025.